Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22.

Autor: Gandhi-Banga S; Sanofi, Toronto, ON, Canada., Wague S; Sanofi, Lyon, France., Shrestha A; Sanofi, Swiftwater, Pennsylvania, USA.; Affiliation at the time of the study; current affiliation Regeneron Pharmaceuticals, Basking Ridge, New Jersey, USA., Syrkina O; Sanofi, Swiftwater, Pennsylvania, USA., Talanova O; Sanofi, Lyon, France., Nissilä M; Terveystalo Biobank and Clinical Research, Turku, Finland., Stuff K; Arztpraxis Dr. Stuff, Donaueschingen, Germany., Monfredo C; Global Biostatistical Sciences, Sanofi, Marcy l'Etoile, France.

Publikováno v: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2023 Jan; Vol. 17 (1), pp. e13071. Date of Electronic Publication: 2022 Nov 29.

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21.

Autor: Syrkina O; Sanofi, Swiftwater Campus, 1 Discovery Drive, Swiftwater, PA, 18370, USA., Inamdar A; Sanofi, Swiftwater Campus, 1 Discovery Drive, Swiftwater, PA, 18370, USA., Wague S; Sanofi, Siège Mondial Campus Sanofi Lyon, 14 Espace Henry Vallée, 69007, Lyon, France., Monfredo C; Global Biostatistical Sciences, Sanofi, 1541 Avenue Marcel Mérieux, 69280, Marcy l'Etoile, France., Nissilä M; Terveystalo Biobank and Clinical Research, Humalistonkatu 7b, 20100, Turku, Finland., Chabanon AL; Sanofi, Siège Mondial Campus Sanofi Lyon, 14 Espace Henry Vallée, 69007, Lyon, France., Serradell L; Sanofi, Siège Mondial Campus Sanofi Lyon, 14 Espace Henry Vallée, 69007, Lyon, France. Laurence.Serradell-vallejo@sanofi.com.

Publikováno v: BMC public health [BMC Public Health] 2022 Aug 08; Vol. 22 (1), pp. 1506. Date of Electronic Publication: 2022 Aug 08.

Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.

Autor: Häppölä P; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland., Gormley P; GlaxoSmithKline, Cambridge, MA, USA.; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.; Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Nuottamo ME; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Folkhälsan Research Center, Helsinki, Finland., Artto V; Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland., Sumelahti ML; Faculty of Medicine and Health, University of Tampere, Tampere, Finland., Nissilä M; Terveystalo Clinical Research, Turku, Finland., Keski-Säntti P; Terveystalo, Helsinki, Finland., Ilmavirta M; Department of Neurology, Central Hospital Central Finland, Jyväskylä, Finland., Kaunisto MA; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland., Hämäläinen EI; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland., Ripatti S; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Public Health, Clinicum, University of Helsinki, Helsinki, Finland., Pirinen M; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Department of Public Health, Clinicum, University of Helsinki, Helsinki, Finland.; Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland., Wessman M; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Folkhälsan Research Center, Helsinki, Finland., Palotie A; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Analytic and Translational Genetics Unit, Department of Medicine, and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA., Kallela M; Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland.

Publikováno v: Cephalalgia : an international journal of headache [Cephalalgia] 2022 Apr; Vol. 42 (4-5), pp. 345-356. Date of Electronic Publication: 2021 Oct 14.

Association between estrogen repctor-1 gene polymorphisms (rs1801132, rs2228480, rs2234693) and migraine susceptibility: an unveiling association through a comprehensive meta-analysis.

Autor: Stephen, Sharon Benita¹ (AUTHOR), Saravanan, Jayakanthan² (AUTHOR), Chandrashekar, Gurudeva³ (AUTHOR), Subbaraj, Gowtham Kumar¹ (AUTHOR) gowtham_phd@yahoo.com

Publikováno v: Egyptian Journal of Medical Human Genetics. 11/20/2024, Vol. 25 Issue 1, p1-15. 15p.

Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season.

Autor: Serradell L; Risk-Benefit & Epidemiology, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France., Wagué S; Medical Operations, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France., Moureau A; Global Biostatistical Sciences, Sanofi Pasteur, Marcy l'Etoile France., Nissilä M; Terveystalo Clinical Research and Biobank, Turku, Finland., Chabanon AL; Global Pharmacovigilance, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Apr 03; Vol. 17 (4), pp. 1205-1210. Date of Electronic Publication: 2020 Sep 23.